Skip to content

US · TCRT · BIOTECHNOLOGY

Alaunos Therapeutics, Inc. (TCRT) intrinsic value and stock valuation

$1.66as of 2026-11-21 · Mkt cap 4.93M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Alaunos Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values TCRT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from TCRT’s statements →

Alaunos Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Fort Lauderdale, FL 33301 alaunos.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$10K
20112025
Net income
-$-4.18M
20112025
Free cash flow
-$-2.97M
20112025
Total equity
$2.15M-55.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$10K$10K$10K$2.92M$400K
Operating income-$-4.22M-$-4.81M-$-34.27M-$-35.1M-$-77.55M
Net income-$-4.18M-$-4.68M-$-35.14M-$-37.73M-$-78.75M
EPSd-$-2.14M-$-2.93M-$-21.96M-$-26.02M-$-55.07M
Operating cash flow-$-2.87M-$-4.97M-$-30.14M-$-29.23M-$-61.47M
Capital expenditure-$-100K$0.00-$-200K-$-220K-$-3.32M
Free cash flow-$-2.97M-$-4.97M-$-30.34M-$-29.45M-$-64.79M
Total assets$2.97M$2.75M$8.26M$64.9M$94.9M
Total debt$0.00$0.00$0.00$20.1M$30.1M
Net debt-$-1.39M-$-1.09M-$-6.06M-$-18.99M-$-45.96M
Total equity$2.15M$2.06M$6.31M$38.6M$58.1M
Cash and short-term investments$1.39M$1.09M$6.06M$39.1M$76.1M
Income statement
20252024202320222021
Revenue$10K$10K$10K$2.92M$400K
Cost of revenue$1.36M$360K$4.8M$22.5M$47.3M
Gross profit-$-1.36M-$-350K-$-4.8M-$-19.6M-$-46.88M
Research and development expenses$1.36M$360K$16.3M$25M$49.6M
Selling, general and administrative expenses$2.87M$4.46M$12.2M$13.1M$26.3M
Other expenses-$-1.36M-$-360K$970K-$-22.65M-$-45.25M
Operating expenses$2.87M$4.46M$29.5M$15.5M$30.7M
Cost and expenses$4.23M$4.82M$34.3M$38M$78M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$1.92M$3.15M$1.19M
Depreciation and amortization$10K$0.00$2.31M$2.76M$2.6M
Ebitda-$-4.17M-$-4.68M-$-30.9M-$-31.82M-$-74.97M
Operating income-$-4.22M-$-4.81M-$-34.27M-$-35.1M-$-77.55M
Total other income/expenses, net$50K$130K-$-870K-$-2.62M-$-1.2M
Income before tax-$-4.18M-$-4.68M-$-35.14M-$-37.73M-$-78.75M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-4.18M-$-4.68M-$-35.14M-$-37.73M-$-78.75M
Weighted average shares outstanding$1.95M$1.6M$1.6M$1.45M$1.43M
Weighted average diluted shares outstanding$1.95M$1.6M$1.6M$1.45M$1.43M
Balance sheet
20252024202320222021
Cash and short-term investments$1.39M$1.09M$6.06M$39.1M$76.1M
Net receivables$0.00$10K$0.00$0.00$1.11M
Inventory$0.00$0.00$0.00$13.9M$0.00
Total current assets$1.99M$2.75M$8.26M$53.8M$78.8M
Property, plant and equipment, net$90K$0.00$0.00$10.6M$15.4M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$980K$0.00$0.00$11.1M$16M
Total assets$2.97M$2.75M$8.26M$64.9M$94.9M
Accounts payable$610K$520K$620K$1.39M$1.37M
Short-term debt$0.00$0.00$0.00$17.9M$9.33M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$810K$690K$1.96M$24.2M$16M
Long-term debt$0.00$0.00$0.00$2.19M$20.8M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$2.22M$20.8M
Capital lease obligations$0.00$0.00$0.00$2.75M$5.25M
Total liabilities$810K$690K$1.96M$26.4M$36.8M
Common stock$0.00$0.00$20K$240K$220K
Retained earnings-$-924.62M-$-920.45M-$-915.77M-$-880.63M-$-842.85M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$2.15M$2.06M$6.31M$38.6M$58.1M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$20.1M$30.1M
Net debt-$-1.39M-$-1.09M-$-6.06M-$-18.99M-$-45.96M
Cash flow statement
20252024202320222021
Net income-$-4.18M-$-4.68M-$-35.14M-$-37.73M-$-78.75M
Depreciation and amortization$10K$0.00$2.31M$2.76M$2.6M
Stock-based compensation$410K$430K$2.8M$3.53M$10.8M
Change in working capital$470K-$-730K-$-6.25M$870K$3.14M
Accounts receivable$0.00-$0.00$0.00$1.11M$3.56M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$100K-$-100K-$-770K-$-30K$270K
Net cash provided by operating activities-$-2.87M-$-4.97M-$-30.14M-$-29.23M-$-61.47M
Investments in property, plant and equipment-$-100K$0.00-$-200K-$-220K-$-3.32M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-100K$0.00$1.35M-$-190K-$-3.32M
Common stock issued$1.91M$0.00$90K$14.7M$0.00
Common stock repurchased$0.00$0.00$0.00-$-40K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$3.26M$0.00-$-18.14M$6.37M$25.8M
Net change in cash$290K-$-4.97M-$-46.93M-$-23.06M-$-39.02M
Cash at end of period$1.39M$1.09M$6.06M$53M$76.1M
Operating cash flow-$-2.87M-$-4.97M-$-30.14M-$-29.23M-$-61.47M
Capital expenditure-$-100K$0.00-$-200K-$-220K-$-3.32M
Free cash flow-$-2.97M-$-4.97M-$-30.34M-$-29.45M-$-64.79M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Alaunos Therapeutics, Inc.

        Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeutics, Inc., a research and development partnership with The University of Texas MD Anderson Cancer Center, and both a patent licensing and R&D agreement with the National Cancer Institute. Previously known as ZIOPHARM Oncology, Inc., the company adopted its current name, Alaunos Therapeutics, Inc., in January 2022. Its headquarters are located in Houston, Texas.

        CEO
        Holger Weis
        Employees
        1
        Beta
        -1.02

        Explore

        Frequently asked questions

        What is the intrinsic value of Alaunos Therapeutics, Inc. (TCRT)?

        InvestorsCraft does not currently publish an intrinsic value for TCRT. How the IC value is calculated.

        Is TCRT undervalued?

        InvestorsCraft does not publish an undervaluation signal for TCRT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.